Preclinical studies demonstrated significant tumor inhibition and complete responses in HER3-high CRC xenografts irrespective of KRAS mutation status, transforming an “undruggable” target into a conduit for delivering immunomodulatory payload. This evidence concerns the gene ERBB3 and colorectal carcinoma.